CN110776469A - 一种5-硝基乳清酸钾晶体及其制备方法 - Google Patents
一种5-硝基乳清酸钾晶体及其制备方法 Download PDFInfo
- Publication number
- CN110776469A CN110776469A CN201911185442.7A CN201911185442A CN110776469A CN 110776469 A CN110776469 A CN 110776469A CN 201911185442 A CN201911185442 A CN 201911185442A CN 110776469 A CN110776469 A CN 110776469A
- Authority
- CN
- China
- Prior art keywords
- potassium
- crystal
- nitro
- orotate
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 34
- 229940069337 potassium orotate Drugs 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229910001414 potassium ion Inorganic materials 0.000 claims abstract description 19
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims abstract description 15
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000011056 potassium acetate Nutrition 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract 3
- WJFDCFHWFHCLIW-UHFFFAOYSA-N 2-(bromomethyl)-6-methylpyridine Chemical compound CC1=CC=CC(CBr)=N1 WJFDCFHWFHCLIW-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- VLUWZLLGDFXCTJ-UHFFFAOYSA-M potassium;5-nitro-2,4-dioxo-1h-pyrimidine-6-carboxylate Chemical compound [K+].[O-]C(=O)C=1NC(=O)NC(=O)C=1[N+]([O-])=O VLUWZLLGDFXCTJ-UHFFFAOYSA-M 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- HVENHVMWDAPFTH-UHFFFAOYSA-N iron(3+) trinitrate hexahydrate Chemical group O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HVENHVMWDAPFTH-UHFFFAOYSA-N 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- OPGJGRWULGFTOS-UHFFFAOYSA-N 5-nitro-2,4-dioxo-1h-pyrimidine-6-carboxylic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1[N+]([O-])=O OPGJGRWULGFTOS-UHFFFAOYSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 abstract description 4
- 235000013361 beverage Nutrition 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 239000000820 nonprescription drug Substances 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000001338 self-assembly Methods 0.000 abstract 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 17
- 229960005010 orotic acid Drugs 0.000 description 9
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- -1 amino orotic acid Chemical compound 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 150000001661 cadmium Chemical class 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 1
- HWCXJKLFOSBVLH-UHFFFAOYSA-N 5-amino-2,4-dioxo-1h-pyrimidine-6-carboxylic acid Chemical compound NC1=C(C(O)=O)NC(=O)NC1=O HWCXJKLFOSBVLH-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229910001374 Invar Inorganic materials 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940003558 aggrenox Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- LTUDISCZKZHRMJ-UHFFFAOYSA-N potassium;hydrate Chemical compound O.[K] LTUDISCZKZHRMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种5‑硝基乳清酸钾晶体及其制备方法，该晶体是由醋酸钾和5‑硝基乳清酸为原料通过自组装反应制备而得，具有明确的空间结构和准确的分子式，其结构单元由两个占有率均为0.5的钾离子、一个5‑硝基乳清酸根和一个配位水分子组成，两个钾离子分别标记为Ka和Kb，晶系为正交，空间群为Pbcn；钾离子Ka为六配位的几何构型，钾离子Kb为十配位的几何构型。所制备的晶体在非处方药物、化妆品基质或饮料的添加剂领域具有广阔的应用前景。本发明合成步骤简单，易操作，适合规模化生产。
Description
技术领域
本发明属于化学领域，具体涉及一种5-硝基乳清酸钾晶体及其制备方法。
背景技术
乳清酸及其衍生物在生物医药、饮料的添加剂以及化妆品等领域的用途，例如其对脂肪肝、黄疸性肝病和急慢性肝炎均有较好的疗效。国内外已经开发出以乳清酸为基础的系列化药物，如硝基乳清酸、氨基乳清酸等。乳清酸及其衍生物具有非对称的空间结构和多种配位官能团，能够和不同的金属离子形成丰富多样的超分子配位化合物。目前，国内外文献报道了一些乳清酸类药物与金属的配合物，这不仅大大丰富了乳清酸类药物超分子配位化学的发展，同时也为挖掘乳清酸及其衍生物在其它方面的应用提供了可能。乳清酸及其衍生物的超分子金属配合物在光电材料领域也显示出潜在的应用前景。中国专利(胡秀峰等，CN102329610B)公开了一种紫色荧光材料，该材料是基于5-硝基乳清酸的超分子镉配合物；殷艺晅等人公开了一种乳清酸超分子镍配合物(一种双核镍配合物及其制备方法，申请号为2017104399847)；在中国化学会第27届学术年会第08分会场摘要集(2010)公开了5-硝基乳清酸Cd(II)超分子化合物，在第十六届全国金属有机化学学术讨论会论文集(2010)公开了5-氨基乳清酸二核、四核镉簇合物。李星等人报道了一系列5-硝基乳清酸的超分子镉配合物(CrystEngComm.,2011,13(21),6373–6376)，其中部分超分子配合物具有较强的荧光发射性能。
在日本，5-硝基乳清酸钾用于复合维生素的非处方药物的成分和清凉饮料的添加剂；在西欧，5-硝基乳清酸钾不仅是医药维生素的组成，而且广泛应用于化妆品中，作为营养型化妆品基质，可以被皮肤细胞吸收，促进细胞的新陈代谢，抑制皮肤衰老；在美国，人们对5-硝基乳清酸钾的研究较多。5-硝基乳清酸钾盐水合物为合成双嘧达莫的关键中间体，双嘧达莫为合成Persantin和Aggrenox的前体。
5-硝基乳清酸具有不同的配位原子和多个配位点，在不同条件下能够与钾离子形成多种多样的氢键结构和晶体结构，不同的晶型和结构使得5-硝基乳清酸钾的溶解速度不同、溶解度不同、密度不同、极性不同、与皮肤细胞的作用不同、或在人体中代谢速度不同，从而导致其作为食品饮料添加剂、药物添加剂或化妆品添加剂应用和作用不同。
发明内容
本发明是针对现有技术，提供5-硝基乳清酸钾晶体及其制备方法。
本发明为解决现有技术问题所采用的技术方案为：一种5-硝基乳清酸钾晶体，该晶体的不对称结构单元是由两个占有率均为0.5的钾离子、一个5-硝基乳清酸根(H2L-)和一个配位水分子组成，两个钾离子分别标记为Ka和Kb，其结构简式为[Ka0.5Kb0.5(H2L)(H2O)]，分子式为KC5H4N3O7，为正交晶系，空间群为Pbcn，晶胞参数
α＝β＝γ＝90°，密度为1.924g/cm3；钾离子Ka为六配位的几何构型，钾离子Kb为十配位的几何构型，不对称结构单元如图1所示。
本发明还提供了5-硝基乳清酸钾晶体的制备方法，所述制备方法包括以下步骤：
取醋酸钾、5-硝基乳清酸和水合硝酸铁置于圆底烧瓶中，加体积比为5～10:1的蒸馏水和乙醇，其中，K+离子、5-硝基乳清酸、Fe3+的摩尔比为4～6:2:1，室温搅拌10min，用KOH调节pH为4～6，然后加热回流反应30～60min，随后转移到锥形瓶中，塞上多孔塞子，置于35～40℃的烘箱中，缓慢挥发溶剂5～7天，得无色片状晶体，即为所述5-硝基乳清酸钾晶体；
所述5-硝基乳清酸简写为H3L，分子式为C5H3N3O6，其结构式为
所述H2L-为失去一个H+的5-硝基乳清酸根；
所述水合硝酸铁为六水合硝酸铁；
所述参加反应的物质或溶剂均为化学纯。
与现有技术相比，本发明的优点在于：
将具有嘧啶环结构的5-硝基乳清酸与钾离子配位，制得5-硝基乳清酸钾超分子配合物晶体，该晶体具有特定的空间结构和准确的分子式；5-硝基乳清酸提供氢键给体和受体，可形成分子间氢键，借助特有的分子间力或氢键的作用，该晶体形成了特定三维网络结构；钾离子是细胞内液的主要阳离子，体内98％的钾存在于细胞内，心肌和神经肌肉都需要有相对恒定的钾离子浓度来维持正常的应激性，本发明所制得5-硝基乳清酸钾晶体化合物具有特定结构，从而使其具有特定的生物活性或生理调节功能。
附图说明
图1为本发明的5-硝基乳清酸钾晶体的不对称结构单元；
图2为本发明的5-硝基乳清酸钾晶体的三维网络结构。
具体实施方式
以下结合实施例对本发明作进一步详细描述。
实施例1：
称取醋酸钾KOAc(0.392g，4.0mmol)、5-硝基乳清酸(0.402g，2.0mmol)、六水合硝酸铁(0.350g，1.0mmol)置于圆底烧瓶中，加蒸馏水20mL和乙醇4.0mL，室温搅拌10min，用KOH调节pH为4，然后加热回流反应30min，随后转移到锥形瓶中，塞上多孔塞子，置于35℃的烘箱中，缓慢挥发溶剂7天，得无色片状晶体。
实施例2：
称取醋酸钾KOAc(0.588g，6.0mmol)、5-硝基乳清酸(0.402g，2.0mmol)、六水合硝酸铁(0.350g，1.0mmol)置于圆底烧瓶中，加蒸馏水30mL和乙醇3.0mL，室温搅拌10min，用KOH调节pH为6，然后加热回流反应60min，随后转移到锥形瓶中，塞上多孔塞子，置于40℃的烘箱中，缓慢挥发溶剂5天，得无色片状晶体。
实施例3：
称取醋酸钾KOAc(0.490g，5.0mmol)、5-硝基乳清酸(0.402g，2.0mmol)、六水合硝酸铁(0.350g，1.0mmol)置于圆底烧瓶中，加蒸馏水30mL和乙醇6.0mL，室温搅拌10min，用KOH调节pH为5，然后加热回流反应45min，随后转移到锥形瓶中，塞上多孔塞子，置于38℃的烘箱中，缓慢挥发溶剂6天，得无色片状晶体.
将上述实施例中制得的无色片状晶体进行X射线单晶衍射测试分析，经测定其不对称结构单元是由两个占有率均为0.5的钾离子、一个5-硝基乳清酸根和一个配位水分子组成，两个钾离子分别标记为Ka和Kb，其结构简式为[Ka0.5Kb0.5(H2L)(H2O)]，分子式为KC5H4N3O7，晶系为正交，空间群为Pbcn，晶胞参数
α＝β＝γ＝90°；钾离子Ka为六配位的几何构型，钾离子Kb为十配位的几何构型；不对称结构单元如图1所示，三维网络结构如图2所示，所制得无色片状晶体即为所述5-硝基乳清酸钾晶体。
Claims (2)
1.一种5-硝基乳清酸钾晶体，其特征在于，该晶体的不对称结构单元是由两个占有率均为0.5的钾离子、一个5-硝基乳清酸根和一个配位水分子组成，两个钾离子分别标记为Ka和Kb，其结构简式为[Ka0.5Kb0.5(H2L)(H2O)]，分子式为KC5H4N3O7，晶系为正交，空间群为Pbcn，晶胞参数α＝β＝γ＝90°，密度为1.924g/cm3；钾离子Ka为六配位的几何构型，钾离子Kb为十配位的几何构型；
所述H2L-为失去一个H+的5-硝基乳清酸根。
2.一种如权利要求1所述的5-硝基乳清酸钾晶体的制备方法，其特征在于，所述制备方法包括以下步骤：
取醋酸钾、5-硝基乳清酸和水合硝酸铁置于圆底烧瓶中，加体积比为5～10:1的蒸馏水和乙醇，其中，K+离子、5-硝基乳清酸、Fe3+的摩尔比为4～6:2:1，室温搅拌10min，用KOH调节pH为4～6，然后加热回流反应30～60min，随后转移到锥形瓶中，塞上多孔塞子，置于35～40℃的烘箱中，缓慢挥发溶剂5～7天，得无色片状晶体，即为所述5-硝基乳清酸钾晶体；
所述水合硝酸铁为六水合硝酸铁；
所述参加反应的物质或溶剂均为化学纯。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911185442.7A CN110776469A (zh) | 2019-11-27 | 2019-11-27 | 一种5-硝基乳清酸钾晶体及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911185442.7A CN110776469A (zh) | 2019-11-27 | 2019-11-27 | 一种5-硝基乳清酸钾晶体及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110776469A true CN110776469A (zh) | 2020-02-11 |
Family
ID=69392910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911185442.7A Pending CN110776469A (zh) | 2019-11-27 | 2019-11-27 | 一种5-硝基乳清酸钾晶体及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110776469A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106905246A (zh) * | 2017-03-10 | 2017-06-30 | 宁波大学 | 一种橙黄色荧光材料及其制备方法 |
| CN106928259A (zh) * | 2017-03-10 | 2017-07-07 | 宁波大学 | 一种青色荧光材料及其制备方法 |
| CN106986899A (zh) * | 2017-05-23 | 2017-07-28 | 宁波大学 | 一种伊马替尼超分子化合物及其制备方法 |
| CN107325294A (zh) * | 2017-06-12 | 2017-11-07 | 宁波大学 | 一种具有多孔二维层状结构的镍化合物及其制备方法 |
| CN108440581A (zh) * | 2018-05-08 | 2018-08-24 | 宁波大学 | 一种5-硝基乳清酸单核锌配合物及其制备方法和用途 |
-
2019
- 2019-11-27 CN CN201911185442.7A patent/CN110776469A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106905246A (zh) * | 2017-03-10 | 2017-06-30 | 宁波大学 | 一种橙黄色荧光材料及其制备方法 |
| CN106928259A (zh) * | 2017-03-10 | 2017-07-07 | 宁波大学 | 一种青色荧光材料及其制备方法 |
| CN106986899A (zh) * | 2017-05-23 | 2017-07-28 | 宁波大学 | 一种伊马替尼超分子化合物及其制备方法 |
| CN107325294A (zh) * | 2017-06-12 | 2017-11-07 | 宁波大学 | 一种具有多孔二维层状结构的镍化合物及其制备方法 |
| CN108440581A (zh) * | 2018-05-08 | 2018-08-24 | 宁波大学 | 一种5-硝基乳清酸单核锌配合物及其制备方法和用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hufziger et al. | Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release | |
| Hirahara et al. | New series of dinuclear ruthenium (II) complexes synthesized using photoisomerization for efficient water oxidation catalysis | |
| CN106366100B (zh) | 一种5-氨基乳清酸双核镉配合物 | |
| Cheng et al. | Synthesis, structure and antitumor studies of a novel decavanadate complex with a wavelike two-dimensional network | |
| Kou et al. | Crystal Structures and Magnetic Properties of New Cyano-Bridged Two-Dimensional Grid-Like Bimetallic Assemblies [Ni (tn) 2] 2 [Cr (CN) 5 ((NO)] OH⊙ H2O and [Ni (tn) 2] 2 [Co (CN) 6] NO3⊙ 2H2O (tn= 1, 3-Propanediamine) | |
| CN108440581B (zh) | 一种5-硝基乳清酸单核锌配合物及其制备方法和用途 | |
| Gale et al. | Antitumor and antimitogenic properties of cis-dichloro (dipyridine) platinum (II) | |
| CN108384017A (zh) | 一种手性Ni（II）氨基酸希夫碱配位聚合物及其制备方法 | |
| Linxin et al. | Study of a new 3D MOF and its adsorption, slow release and biological activity in water-soluble and oil-soluble pesticides | |
| CN109096207B (zh) | 一种5-氟尿嘧啶与二甲双胍的盐、其制备方法及晶体结构 | |
| CN110776469A (zh) | 一种5-硝基乳清酸钾晶体及其制备方法 | |
| CN106995467B (zh) | 一种微波催化合成双环铂的方法 | |
| CN101696218B (zh) | 一种邻氨基吡啶铜配合物的制备方法 | |
| Yang et al. | One-dimensional chain structures constructed from tetra (acetamidato) dirhodium (II, III) complexes and square planar platinum and palladium complexes | |
| CN111747889B (zh) | 一种含多个配位点的NNO型喹啉Fe(II)配合物及其制备方法和应用 | |
| CN106939023A (zh) | 基于手性席夫碱配体的锰离子配合物及制备方法与应用 | |
| CN106957270A (zh) | 一种硝基尿嘧啶药物超分子共晶及其制备方法 | |
| CN106883251A (zh) | 一种氨基酸多吡啶铜配合物及其制备方法和应用 | |
| CN106478694A (zh) | 一种锶的配合物及其制备方法 | |
| Rein et al. | Crystal structure of a mononuclear RuII complex with a back-to-back terpyridine ligand:[RuCl (bpy)(tpy–tpy)]+ | |
| CN102898447B (zh) | 一种金属锌配合物三维有序多孔材料及其制备方法 | |
| Gao et al. | Study on the interaction of a palladium complex with DNA | |
| Liu et al. | Rare Silver–Histidine Cluster Complex and Its Single-Crystal-to-Single-Crystal Phase-Transition Behavior | |
| CN107759800B (zh) | 一种烟酸对乙酰氨基苯酯铜配位聚合物及其制备方法 | |
| CN106986899A (zh) | 一种伊马替尼超分子化合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200211 |